Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 4Phase 3 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Nasopharyngeal Carcinoma 26Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Nasopharyngeal Neoplasms 6Head and Neck Neoplasms 6Breast Neoplasms 5Uterine Cervical Neoplasms 4Oropharyngeal Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Tongue Neoplasms 2Salivary Gland Neoplasms 2Radiation Injuries 2Neurotoxicity Syndromes 2Hypopharyngeal Neoplasms 2Glioblastoma 2Carcinoma 2Brain Neoplasms 2Astrocytoma 2Vaginal Neoplasms 1Thoracic Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1Sarcoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Pancreatic Intraductal Neoplasms 1Pancreatic Adenocarcinoma 1Ototoxicity 1Oligodendroglioma 1

Interventions

Radiosurgery 23Radiotherapy 20Temozolomide 17Lomustine 9Bevacizumab 8Surgical Procedures, Operative 7Procarbazine 6Vincristine 5Nivolumab 5Memantine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Etoposide 4Cisplatin 4Carboplatin 4Specimen Handling 3Sodium Chloride 3Radiation 3Methylphenidate 3Mental Status and Dementia Tests 3Granulocyte Colony-Stimulating Factor 3Gefitinib 3Cyclophosphamide 3Corticotropin-Releasing Hormone 3Carmustine 3icotinib 2etoposide phosphate 2efaproxiral 2X-Rays 2Tranexamic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Brain Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT00978458 2025-09-08

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
540 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

NCT02360215 2025-04-23

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NRG Oncology

Phase 3 Completed
518 enrolled 40 charts
CNS

Brain Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡